Recent advances in BNP/NT-proBNP biosensors achieve femtogram-to-picogram limits of detection, though gaps remain between laboratory performance and clinical implementation.
In the past five years, rapid progress has been made in biosensor platforms for BNP and NT-proBNP detection. Innovations span fluorescence-based assays (FRET aptasensors, quantum dots, NIR persistent luminescence probes), colorimetric nanozyme-enhanced lateral flow assays, surface-enhanced Raman scattering (SERS) systems and electrochemiluminescence immunoassays. These strategies exploit advances in nanomaterials, photonic engineering, and biointerface design to achieve femtogram-to-picogram limits of detection, multiplex biomarker analysis, and smartphone-compatible readouts. Parallel work on biofouling mitigation through zwitterionic coatings, hydrogel nanocomposites, and MOF encapsulation can be adapted for further enhance sensor robustness in complex biological fluids. This review critically evaluates BNP/NT-proBNP detection technologies reported between 2020 and 2025, comparing analytical performance, material design, and translational potential. We highlight gaps between laboratory performance and clinical implementation, discuss harmonisation with established commercial assays, and outline future directions in multiplexed panels, wearable monitoring, and digital health integration. By synthesizing recent advances, this work provides a roadmap toward biosensors capable of transforming HF care through earlier diagnosis, decentralised testing, and proactive disease management.
Elahi et al. (2025) conducted a review in Heart Failure. BNP/NT-proBNP biosensors was evaluated. Recent advances in BNP/NT-proBNP biosensors achieve femtogram-to-picogram limits of detection, though gaps remain between laboratory performance and clinical implementation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: